公开(公告)号：US20230314452A1

公开(公告)日：2023-10-05

申请号：US18021085

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G16H50/30

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of IGFBP7 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210181211A1

公开(公告)日：2021-06-17

申请号：US17176797

申请日：2021-02-16

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.

公开(公告)号：US20200300869A1

公开(公告)日：2020-09-24

申请号：US16899629

申请日：2020-06-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Ursula-Henrike Wienhues-Thelen ,  Johann Karl ,  Peter Kastner ,  Vinzent Rolny ,  Andre Ziegler ,  David Conen

IPC: G01N33/68

Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.

公开(公告)号：US20190162737A1

公开(公告)日：2019-05-30

申请号：US16264779

申请日：2019-02-01

Applicant: Roche Diagnostics Operations, Inc. ,  Maastricht University Medical Center

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  Manuel Dietrich ,  Ulrich Schotten ,  Vinzent Rolny

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of ESM-1 in a sample from the subject, and comparing the amount of ESM-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.

公开(公告)号：US20230366894A1

公开(公告)日：2023-11-16

申请号：US18028235

申请日：2021-09-30

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Serge Masson ,  Jennifer Marie Theresia Anna Meessen ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler

IPC: G01N33/74

CPC classification number: G01N33/74 ,  G01N2333/58 ,  G01N2440/38 ,  G01N2800/326

Abstract: The present invention relates to a method for diagnosing atrial fibrillation in a subject, said method comprising the steps of a) determining the amount of total NT-proBNP in sample from the subject, b) determining the amount of unglycosylated NT-proBNP in a sample from the subject, c) calculating a score of the amounts determined in steps a) and b), d) comparing the calculated score with a reference score, and e) diagnosing atrial fibrillation in a subject.

公开(公告)号：US20230296630A1

公开(公告)日：2023-09-21

申请号：US18021021

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Michael Kuehne ,  Stefan Osswald

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/2814

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amounts of the biomarkers Osteopontin, cardiac Troponin, a natriuretic peptide and FABP-3 in a sample from the subject, b) comparing the amounts determined in step a) to references, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210239712A1

公开(公告)日：2021-08-05

申请号：US17181390

申请日：2021-02-22

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Zickenhuis Maastricht

Inventor： Peter Kastner ,  Andre Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.

公开(公告)号：US20210172962A1

公开(公告)日：2021-06-10

申请号：US17172761

申请日：2021-02-10

Applicant: Roche Diagnostics Operations, Inc. ,  UNIVERSITEIT MAASTRICHT ,  AKADEMISCH ZIEKENHUIS MAASTRICHT

Inventor： Manuel Dietrich ,  Peter Kastner ,  Vinzent Rolny ,  Ulrich Schotten ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.

公开(公告)号：US20190353666A1

公开(公告)日：2019-11-21

申请号：US16217612

申请日：2018-12-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Herbert Andres ,  Dirk Block ,  Johann Karl ,  Peter Kastner ,  Ursula-Henrike Wienhues-Thelen ,  Roberto Latini ,  Serge Masson ,  Andre Ziegler ,  Edelgard Kaiser ,  Stefan Palme ,  Markus Thomas ,  Simona Barlera

IPC: G01N33/68

Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.

公开(公告)号：US20150355199A1

公开(公告)日：2015-12-10

申请号：US14835821

申请日：2015-08-26

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Alfred Engel ,  Andreas Gallusser ,  Johann Karl ,  Peter Kastner ,  Wolfgang Obermeier ,  Monika Soukupova

IPC: G01N33/68 ,  C07K16/18 ,  G01N33/543

CPC classification number: C07K16/18 ,  C07K14/472 ,  C07K2317/30 ,  C07K2317/33 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/92 ,  G01N33/54306 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2800/28 ,  G01N2800/2814 ,  G01N2800/30 ,  G01N2800/52

Abstract: The present invention relates to an assay for specific detection of complement factor H-related protein 1 (CFHR1) in a sample from a subject, as well as kits and agents related thereto.

Abstract translation: 本发明涉及用于特异性检测来自受试者的样品中的补体因子H相关蛋白1（CFHR1）的测定，以及与其相关的试剂盒和试剂。